NM
NMRD.US Nemaura Medical Inc
- Market cap
- USD 4.04K
- P/E
- -
- P/B
- 122.56x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Dec 2023.
Is NMRD.US undervalued?
Graham numberThe Graham number of Nemaura Medical Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nemaura Medical Inc fundamental analysis
No fundamental analysis for Nemaura Medical Inc yet.
Nemaura Medical Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nemaura Medical Inc
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and re…
Full company profileNemaura Medical Inc financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 3 quarters up to Dec 31, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Nemaura Medical Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 504K | 77.0K | -2.07M |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | -98.1K | 160K | -1.48M | -6.22M |
| Operating Income | -586K | -1.32M | -1.54M | -1.55M | -1.91M | -4.48M | -4.78M | -4.59M | -7.57M | -9.60M | -7.23M |
| EBITDA | -581K | -1.31M | -1.52M | -1.53M | -1.88M | -4.44M | -4.72M | -4.49M | -7.34M | -7.29M | -3.00M |
| Net Income | -586K | -1.32M | -1.54M | -1.55M | -1.82M | -4.45M | -4.16M | -6.26M | -13.9M | -14.1M | -7.96M |
| EPS | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 | -0.25 | -0.20 | -0.28 | -0.59 | -0.57 | -0.28 |
| Balance Sheet | |||||||||||
| Total Assets | 2.05M | 913K | 9.73M | 7.40M | 6.26M | 4.76M | 1.22M | 35.2M | 22.1M | 14.6M | 5.17M |
| Total Liabilities | 1.68M | 1.83M | 2.05M | 2.04M | 2.14M | 2.54M | 2.53M | 26.9M | 21.6M | 26.4M | 23.0M |
| Shareholders' Equity | 374K | -917K | 7.68M | 5.37M | 4.11M | 2.23M | -1.31M | 8.36M | 466K | -11.8M | -17.8M |
| Cash & Short-term Investments | 1.87M | 355K | 9.40M | 2.78M | 5.73M | 3.74M | 106K | 31.9M | 17.7M | 10.1M | 137K |
| Total Debt | - | - | - | - | - | - | 82.6K | 24.9M | 19.2M | 20.0M | 19.6M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.50M | -1.43M | -1.21M | -1.19M | -2.14M | -3.56M | -3.45M | -6.00M | -6.50M | -8.45M | -9.60M |
| Capital Expenditure | 12.4K | 92.2K | 87.6K | 79.6K | 45.3K | 80.0K | 211K | 836K | 956K | 539K | 102K |
| Free Cash Flow | 1.49M | -1.53M | -1.30M | -1.27M | -2.18M | -3.64M | -3.66M | -6.83M | -7.46M | -8.99M | -9.71M |
| Ratios | |||||||||||
| ROE | -156.8% | - | -20.1% | -28.9% | -44.3% | -200.0% | - | -74.9% | -2,979.5% | - | - |
| ROA | -28.6% | -144.5% | -15.8% | -21.0% | -29.1% | -93.5% | -341.0% | -17.8% | -62.8% | -97.1% | -153.9% |
| Net Profit Margin | - | - | - | - | - | - | - | - | -2,755.8% | -18,358.0% | - |
| Debt to Equity | - | - | - | - | - | - | - | 2.98x | 41.17x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Nemaura Medical Inc dividends
Nemaura Medical Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Dec 5, 2019.
Who owns Nemaura Medical Inc
Top funds holding NMRD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| SSgA U.S. Extended Market Index Class I | 7.49K | 0.02% | 0.00% | Dec 2023 |
| NT US Market Cap Idx Fd - L | 841.00 | 0.00% | 0.00% | Dec 2023 |
| BlackRock Extended Mkt Composite | 548.00 | 0.00% | 0.00% | Sep 2023 |
Top institutions holding NMRD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| XTX Topco Ltd | 18.9K | 0.07% | -11.51% | Mar 2024 |
| Ronald Blue Trust, Inc. | 500.00 | 0.00% | 0.00% | Dec 2023 |
| Royal Bank of Canada | 491.00 | 0.00% | +83.21% | Dec 2023 |
| HAZLETT, BURT & WATSON, INC. | 30.00 | 0.00% | 0.00% | Dec 2023 |
| State Street Corporation | 0.00 | 0.00% | -100.00% | Mar 2024 |
| Susquehanna International Group, LLP | 0.00 | 0.00% | -100.00% | Dec 2023 |
| Wells Fargo & Co | 0.00 | 0.00% | -100.00% | Mar 2024 |
| Tower Research Capital LLC | 0.00 | 0.00% | -100.00% | Mar 2024 |
| Goss Wealth Management LLC | 0.00 | 0.00% | -100.00% | Mar 2024 |
| Northern Trust Corp | 0.00 | 0.00% | -100.00% | Mar 2024 |
| UBS Group AG | 0.00 | 0.00% | -100.00% | Mar 2024 |
| Salomon & Ludwin, LLC | 0.00 | 0.00% | -100.00% | Mar 2024 |
| Morgan Stanley - Brokerage Accounts | 0.00 | 0.00% | -100.00% | Mar 2024 |
| Qube Research & Technologies | 0.00 | 0.00% | -100.00% | Mar 2024 |
| Vanguard Group Inc | 0.00 | 0.00% | -100.00% | Mar 2024 |
| Geode Capital Management, LLC | 0.00 | 0.00% | -100.00% | Mar 2024 |
| JPMorgan Chase & Co | 0.00 | 0.00% | -100.00% | Mar 2024 |
| Alyeska Investment Group, L.P. | 0.00 | 0.00% | -100.00% | Mar 2024 |
| Virtu Financial LLC | 0.00 | 0.00% | -100.00% | Dec 2023 |
| BlackRock Inc | 0.00 | 0.00% | -100.00% | Mar 2024 |
Nemaura Medical Inc company profile
- Company name
- Nemaura Medical Inc
- Ticker
- NMRD.US
- Exchange
- USA Stocks
- Listed since
- Mar 4, 2016
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 36
- Fiscal year end
- March
- Address
- 57 West 57th Street, New York, NY, United States, 10019
- Phone
- 646 416 8000
- Website
- nemauramedical.com
About Nemaura Medical Inc
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
Nemaura Medical Inc management
5- Dr. Dewan Fazlul Hoque Chowdhury Ph.D.Chairman, Interim CFO, CEO, President and Principal Financial & Accounting Officer · born 1973
- Dr. Arash GhadarChief Operating Officer · born 1977
- Mr. Jay L. Warner M.B.A.Head of U.S. Commercial Operations
- Mr. Thomas Bendix MortensenHead of E.U. Commercial Operations & Marketing
- Ms. Samantha SandersGlobal Head of Digital Programs